10、oup (COG,Blood: 2007; 109: 926935,Retrospective,CCG:1988-1995,POG:1986-1999,N=6238,Age:1-22y,COG risk classification scheme,Risk factors: Age:10 y WBC:50000/L Cytogenetics:TEL/AML1,Trisomies(4,10.17),BCR/ABL,MLL, Day-14 marrow response:M125% blast Day-29 MRD-FCM CNS/TD,Child...
微量残留病检测在急性白血病分层治疗中的意义 MinimalResidualDisease(MRD)MRD:TheleukemicpopulationundectablebymorpglogicmethodshasbeendefinedasMRD MRDisatermusedwhenthereisevidence(immunophenotypic,molecular,orcytogenetic)thatleukemiccellsremainintheBMbutthereareinsufficientcellstobedetectedbyroutineexaminationunderthe...
inhibitor (TKI) treatment guided by circulating tumor DNA (ctDNA) for achieving complete remission after local consolidative therapy (LCT) in patients with advanced NSCLC.OBJECTIVEThis prospective nonrandomized trialwas conducted at a single center from June 3, 2020, to July 19, 2022, and included...
Retrospective,CCG:1988-1995,POG:1986-1999,N=6238,Age:1-22y COG risk classification scheme Risk factors: Age:10 y WBC:50000/ L Cytogenetics:TEL/AML1,Trisomies(4,10.17),BCR/ABL,MLL, Day-14 marrow response:M1<5%.M2:5-25%,M3:>25% blast Day-29 MRD-FCM CNS/TD 27 Childhood B-...
3206 Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute Lymphoblastic leukemia:results in 3184 patients of the AIEOP-BFM ALL 2000 study TEL/AML1+ favorable DNA index ( 1.16 and 1.6) PCR-MRD对预后好患者的影响 PCR-MRD 对Ph+ ...
Myeloid leukemia of Down syndrome (ML-DS) is associated with good response to chemotherapy, resulting in favorable outcomes. However, no universal prognostic factors have been identified to date. To clarify a subgroup with high risk of relapse, the role
MUD group differed from MRD group by following factors: younger age (p=0.020), longer time to HSCT (p 2 grade (26 in MFD and 16 in MUD) and 27 pts extensive chronic GVHD (23 in MFD and 4 in MUD). Mean survival, estimated 5-yrs OS, probabilities of GVHD incidence, relapse and ...
Borowitz MJ, Devidas M, Bowman WP, et al.: Prognostic significance of minimal residual disease (MRD) in childhood B-precursor ALL and its relation to other risk factors. A Children’s Oncology Group (COG) study [abstract] . Blood (ASH Annual Meeting Abstracts) 2006, 108: 69a (Abstract ...
Minimal residual disease (MRD) is considered the strongest relevant predictor of prognosis and an effective decision-making factor during the treatment of hematological malignancies. Remarkable breakthroughs brought about by new strategies, such as epige
In ALL, MRD-based risk classifications clearly outweigh established prognostic factors, including favorable-risk genetics.1 (2) In the trial by Loken et al, patients with MRD > 0% to < 1% and those with > 1% after the first course of induction had similar relapse-free survival, which was...